The compound demonstrated robust protein degradation up to 98% at 100 nM concentrations and improved anticancer efficacy compared to previously reported BRD4 PROTACs across various cancer cell types, including colorectal cancer, melanoma, and lung cancer cells. This evidence concerns the gene BRD4 and cancer.